Objective:
To discuss the need for neuroprotection in glaucoma and explore new therapeutic opportunities targeting ganglion cells, axons, and vascular support.
Key Findings:
- Inhibition of the DLK/LZK pathway can protect ganglion cells even under high intraocular pressure.
- Maintaining NAD+ levels is crucial for preventing axonal degeneration.
- Antagonizing endothelin may improve visual field function and blood flow.
Interpretation:
The evolving understanding of glaucoma pathophysiology opens new avenues for neuroprotective therapies that could significantly improve patient outcomes.
Limitations:
- Clinical trials historically require large patient populations and long follow-up periods.
- FDA guidelines may pose challenges for new trial designs.
Conclusion:
The future of neuroprotection in glaucoma is promising, with innovative strategies and clinical trial designs that could enhance patient care.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.